Insmed reported $210.77M in Operating Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Acelrx Pharmaceuticals ACRX:US USD 7.14M 7M
Alimera Sciences ALIM:US USD 17.01M 431K
Biomarin Pharmaceutical BMRN:US USD 562.04M 54.28M
Cytokinetics CYTK:US USD 128.99M 4.22M
Dynavax Technologies DVAX:US USD 121.36M 15.02M
Gilead Sciences GILD:US USD 5.12B 917M
Heron Therapeutics HRTX:US USD 68.44M 8.69M
Insmed INSM:US USD 210.77M 15.35M
Mirati Therapeutics MRTX:US USD 212.66M 20.78M
Novartis NVS:US USD 11.05B 378M
Regeneron Pharmaceuticals REGN:US USD 2.27B 555.1M
Sarepta Therapeutics SRPT:US USD 367.84M 119.23M
Seattle Genetics SGEN:US USD 682.15M 20.95M
Ultragenyx Pharmaceutical RARE:US USD 248.98M 66.79M
Vertex Pharmaceuticals VRTX:US USD 1.27B 61.6M